PMID- 21122981
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20211203
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 301
IP  - 1
DP  - 2011 Feb 1
TI  - Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) 
      signaling pathway delays cell cycle progression and alters adhesion behavior of 
      prostate carcinoma cells.
PG  - 17-28
LID - 10.1016/j.canlet.2010.11.003 [doi]
AB  - The impact of the mTOR inhibitor RAD001 combined with the EGFr/VEGFr tyrosine 
      kinase inhibitor AEE788 on prostate tumor cell growth, adhesion and migration was 
      analyzed in vitro. The RAD001-AEE788 combination profoundly reduced 
      tumor-endothelium and tumor-matrix contacts, suppressing cell growth and cell 
      cycle progression. The underlying molecular mode of action depended on the cell 
      phenotype, since cell cycle proteins, integrin subtype expression and integrin 
      dependent signaling were altered in a different manner in PC-3 and DU-145 versus 
      LNCaP prostate cancer cells. Simultaneous targeting of mTOR and VEGFr/EGFr 
      related pathways may offer a novel therapeutic strategy for prostate cancer 
      treatment.
CI  - Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Wedel, Steffen
AU  - Wedel S
AD  - Department of Urology, Johann Wolfgang Goethe-University, Frankfurt am Main, 
      Germany.
FAU - Hudak, Lukasz
AU  - Hudak L
FAU - Seibel, Jens-Michael
AU  - Seibel JM
FAU - Juengel, Eva
AU  - Juengel E
FAU - Tsaur, Igor
AU  - Tsaur I
FAU - Haferkamp, Axel
AU  - Haferkamp A
FAU - Blaheta, Roman A
AU  - Blaheta RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101130
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Purines)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - F9JLR95I3I (AEE 788)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Cell Adhesion/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - ErbB Receptors/*antagonists & inhibitors/physiology
MH  - Everolimus
MH  - Humans
MH  - Male
MH  - Neoplasm Invasiveness
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Protein Kinase Inhibitors/*pharmacology/therapeutic use
MH  - Purines/pharmacology
MH  - Receptors, Vascular Endothelial Growth Factor/*antagonists & 
      inhibitors/physiology
MH  - Signal Transduction/*drug effects
MH  - Sirolimus/analogs & derivatives/pharmacology
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/physiology
EDAT- 2010/12/03 06:00
MHDA- 2011/02/04 06:00
CRDT- 2010/12/03 06:00
PHST- 2010/06/21 00:00 [received]
PHST- 2010/11/04 00:00 [revised]
PHST- 2010/11/07 00:00 [accepted]
PHST- 2010/12/03 06:00 [entrez]
PHST- 2010/12/03 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
AID - S0304-3835(10)00528-8 [pii]
AID - 10.1016/j.canlet.2010.11.003 [doi]
PST - ppublish
SO  - Cancer Lett. 2011 Feb 1;301(1):17-28. doi: 10.1016/j.canlet.2010.11.003. Epub 
      2010 Nov 30.